Organon & Co Stock Discussion

$Organon & Co(OGN.US)$ 📈

U.S. stocks were lower after the close on Tuesday, as losses in the Basic Materials, Financials and Technology sectors led shares lower.
At the close in NYSE, the Dow Jones Industrial Average fell 0.45%, while the S&P 500 index lost 0.42%, and the NASDAQ Composite index lost 0.79%.
The best performers of the session on the Dow Jones Industrial Average were Amgen Inc ( $Amgen(AMGN.US)$ ), which rose 3.11% or 7.86 points t...

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Novo-Nordisk A/S(NVO.US)$ - up 13.4%
2. $Eli Lilly and Co(LLY.US)$ - up 10.5%
3. $James Hardie Industries(JHX.US)$ - up 10.1%
4. $New York Times(NYT.US)$ - up 3.3%
5. $POSCO(PKX.US)$ - up 2.9%
6. $Fox Corp-B(FOX.US)$ - up 2.8%
7. $Fox Corp-A(FOXA.US)$ - up 2.8%
8. $West Pharmaceutical Services(WST.US)$ - up 2.5...

$Organon & Co(OGN.US)$ my sell limit is set . Will OGN reach $28.00 a share today  ?
even right now

Loop Capital Starts Micron at Buy Ahead of DRAM Bottom
Loop Capital analyst Charles Park initiated coverage of $Micron Technology(MU.US)$ with a Buy rating and $70 price target. The analyst expects DRAM fundamentals to bottom in the first half of 2023 and notes that the shares "typically bottoming a couple of quarters ahead."
AppLovin Initiated With an Outperform at Wedbush
Wedbush analyst Nick McKay initiated coverage of $Applovin(APP.US)$ with an O...

$Dare Bioscience(DARE.US)$ is gearing up to launch its study of Ovaprene, a monthly hormone free women's contraceptive that they have partnership with $BAYER AG(BAYRY.US)$ on. They announced that the FDA has approved the study and expect to enroll mid-2023.
Darė already has FDA approval for Xaciato with which they announced a partnership with $Organon & Co(OGN.US)$ and expect revenues to begin generating in Q4 2022.
This is a promising bio for the patient investor IMO...